Lonza has unveiled plans to manufacture clinical supply materials for Kodiak Science at multiple sites including Slough, UK, Visp, Switzerland and Nansha, China. Kodiak’s drug candidates have the goals of restoring vision, slowing disease progression while requiring fewer treatments. Retinal diseases, such as age-related macular degeneration (AMD), cause blindness by damaging the retina, typically in those over 50 years of age. As the world’s population ages, retinal diseases will...